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Background: Regorafenib improves progression free survival (PFS) in a subset of
metastatic colorectal cancer (mCRC) patients, although no biomarkers of efficacy are
available. Circulating methylated DNA (cmDNA) assessed by a five-gene panel was
previously associated with outcome in chemotherapy treated mCRC patients. We
hypothesized that cmDNA could be used to identify cases most likely to benefit from
regorafenib (i.e., patients with PFS longer than 4 months).
Methods: Plasma samples from mCRC patients were collected prior to (baseline
samples N = 60) and/or during regorafenib treatment (N = 62) for the assessment of
cmDNA and total amount of cell free DNA (cfDNA).
Results: In almost all patients, treatment with regorafenib increased the total cfDNA,
but decreased cmDNA warranting the normalization of cmDNA to the total amount of
circulating DNA (i.e., cmDNA/ml). We report that cmDNA/ml dynamics reflects clinical
response with an increase in cmDNA/ml associated with higher risk of progression (HR
for progression = 1.78 [95%CI: 1.01–3.13], p = 0.028). Taken individually, high baseline
cmDNA/ml (above median) was associated with worst prognosis (HR for death = 3.471
[95%CI: 1.83–6.57], p < 0.0001) and also predicted shorter PFS (<16 weeks with PPV
86%). In addition, high cmDNA/ml values during regorafenib treatment predicted with
Amatu et al. Regorafenib Benefit and Circulating Methylated DNA
higher accuracy shorter PFS (<16 weeks with a PPV of 96%), therefore associated
with increased risk of progression (HR for progression = 2.985; [95%CI: 1.63–5.46;
p < 0.0001).
Conclusions: Our data highlight the predictive and prognostic value of cmDNA/ml in
mCRC patients treated with regorafenib.
Keywords: regorafenib, DNA methylation, metastatic colorectal cancer, cell free circulating DNA, liquid biopsy,
digital PCR, biomarkers, prognosis
BACKGROUND
Colorectal cancer (CRC) remains the third most common
cancer in men and women worldwide (1). The advent of new
therapeutic agents has enhanced themedian overall survival (OS)
up to 30 months for metastatic CRC (mCRC) patients (2, 3).
Among the new lines of treatment added to the therapeutic
armamentarium of mCRC, regorafenib is a multikinase inhibitor
targeting angiogenic and oncogenic activities in the tumor and
its stroma. It has demonstrated single agent efficacy in preclinical
cancer models (4, 5) and in patients with chemo-refractory
mCRC (6). In 2013, the phase III CORRECT study (7) showed a
median OS improvement of 1.4 months, leading to the approval
of regorafenib by the EMA. While mCRC patients treated with
regorafenib achieved a response rate of 1% and a 16-week disease
control rate in 19% cases, up to 54% individuals experienced
grade 3 or 4 treatment related adverse events such as hand-
foot skin reaction, fever, and fatigue, which severely impair
quality of life (8). Consequently, the overall clinical benefit
from regorafenib remains rather limited. While no validated
biomarkers are available to prospectively identify individuals who
could benefit from this drug, several studies have previously
explored the use of circulating biomarkers.
A retrospective exploratory analysis of the CORRECT
trial showed that baseline circulating total cell free DNA
concentration was prognostic rather than predictive for clinical
outcome; since both placebo and regorafenib provided a
consistent survival benefit in a subset of patients based on
low amount of tumor mutation and plasma protein biomarker
concentrations (9). Another retrospective analysis by Komori
et al. demonstrated that an early decrease in serum CA19–
9 protein levels could predict for regorafenib efficacy and
was associated with better progression free survival (PFS) in
mCRC (10). In a phase II study, a profound decrease of
RAS mutant clones in circulating tumor DNA (ctDNA) was
associated with better PFS in 21 mCRC patients after 8 weeks
of treatment with regorafenib, together with modification at
dynamic contrast-enhanced MRI (11). Finally, Vandeputte et al.
showed the prognostic value of monitoring genetic alterations
in the ctDNA of a small cohort of 20 patients. This approach
implied next generation sequencing of patient primary tumors
Abbreviations: CEA, carcinoembryonic antigen; cfDNA, cell free circulating
DNA; ctDNA, cfDNA of tumor origin; cmDNA, circulating methylated DNA;
CRC, colorectal cancer; HR, hazard ratio; LB, liquid biopsy; LDH, lactate
dehydrogenase; mCRC, metastatic CRC; OR, odds ratio; OS, overall survival; PFS,
Progression free survival; RECIST, Response Evaluation Criteria in Solid Tumors.
and optimization of personalized assays for mutation tracking in
plasma (12).
The above-mentioned circulating biomarker studies in mCRC
patients undergoing regorafenib treatment were either based
on a single parameter or on panels of genetic alterations
requiring expensive and time-consuming personalized assay
design. Nevertheless, simpler and more universally applicable
biomarker would be desirable to improve cost-effectiveness of
regorafenib treatment.
We and others recently demonstrated that cancer specific
DNA methylation could represent a promising analyte for
circulating tumor markers. Thanks to its stability and its
specificity to cancer, CRC epigenetic alterations could be detected
in plasma cell free DNA at higher prevalence and with a higher
allelic ratio than genetic alterations. Some of these methylated
loci were also identified as early events in the carcinogenesis
process, representing promising cancer specific tools for early
diagnosis using blood tests (13–20).
We previously identified a panel of five methylated genes
(EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC) and used it in a
liquid biopsy (LB) test to monitor mCRC tumor burden over
the course of conventional chemotherapy regimens (21). Yet, the
dynamics of ctDNA under treatment with regorafenib remains to
be investigated.
Inspired by data of two recent studies (11, 12) with limited
number of patients and using exclusively genetic alterations,
we hypothesized that dynamics of circulating methylated DNA
(cmDNA) may stratify mCRC patients treated with regorafenib
according to their clinical outcome sparing a subgroup of
unresponsive patients from prolonged drug exposure.
PATIENTS AND METHODS
Patient Selection and Study Design
We selected 76 mCRC patients who received regorafenib at
Niguarda Cancer Center, NCC (Milano) or Istituto Oncologico
Veneto, IOV (Padova) from December 2012 to August
2017 (Supplementary Table S1). LB samples were collected
prospectively and analyzed retrospectively in double blind
fashion for patient outcome (Figure 1).
Eligible patients had histologically confirmed metastatic
adenocarcinoma of the colon or rectum, performance status (PS)
0–1, adequate organ function, age >18 years, life expectancy
of at least 12 weeks (based on physician’s prognostication
according to patient age, ECOG performance status, general
conditions, comorbidities, and lab tests including renal and liver
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FIGURE 1 | Time to progression of patients enrolled in the study with sample availability and informativeness. Blood draws are represented with filled circles and
colored in black when cmDNA/ml was above median, depicted in white when cmDNA/ml was below median; red circles label samples that were not informative (i.e.,
no positive markers). Patients were sorted by duration of progression free survival. Sixty baseline (among which 57 informative) and 62 under treatment blood draws
(among which 56 informative) were available. Fifty seven patients had both types of blood draws available (among which 52 informative in both cases). Two cases
were censored for follow-up. Imaging CT-scans are also indicated.
function), and were refractory or intolerant to conventional 5-
FU-based chemotherapy treatments. Patients received 160mg of
regorafenib orally once daily for the first 3 weeks of each 4-week
cycle, with dose reduction according to physician’s discretion and
current guidelines (Supplementary Tables S1, S2).
Blood was collected at baseline (prior to regorafenib start)
and/or then biweekly or at any subsequent access to the hospital,
during regorafenib treatment.
All the patients provided written informed consent to LB
collection before and during regorafenib treatment. Protocol for
blood collection and analysis was approved from NCC and IOV
institutional Ethics Committees.
Assessment of Cell Free Circulating
DNA Markers
Analysis of cell free circulating DNA (cfDNA) via a panel of
methylated CRC-specific genes was carried out on blood as
previously described (21).
We defined a value of cmDNA compiled as the methylation
average of the markers demonstrating positivity above the
previously published thresholds (21), supported by number of
methylated events above the limit of detection. In subsequent
longitudinal LB, for each patient, calculation was based
exclusively on the loci used to compile the cmDNA in
the baseline.
Additionally, blood samples from carriers of tumors with
KRAS, NRAS, or BRAF mutations were also analyzed by digital
droplet PCR commercial assay for the QX200 system (Biorad).
All PCR amplifications were performed in duplicate.
Data Collection
The following data were collected from medical records:
patient characteristics, PS, presence of tumor in-situ,
number and sites of metastases, mutational status of KRAS,
NRAS, and BRAF, amplification of HER2, and MSI status,
baseline lactate dehydrogenase (LDH), carcinoembryonic
antigen (CEA).
Tumor response was evaluated according to Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CT
scan was performed every 8 weeks from treatment start. PFS was
defined as the time from initiation of regorafenib treatment to
either radiological or clinical disease progression or death from
any reason.
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OS was defined as the time from initiation of regorafenib
treatment to death from any reason. The cut-off for analyses and
follow-up for survival status was 1st March 2018.
Information about regorafenib associated toxicities and dose
reduction can be found in Supplementary Table S1 and are
summarized in Supplementary Table S2.
Statistical Analysis
All analyses were carried out using the STATA (22) and R
software (23). Univariate and multivariate analysis were carried
out in all evaluable patients (Figure 1). Hazard ratios and 95%
CIs for PFS and OS were calculated using the stratified Cox
model. Kaplan–Meier curves and comparison were computed
using GraphPad 7 (Prism). All other analyses were descriptive.
All P-values are two-sided.
RESULTS
Patient characteristics are summarized in Table 1. A total of
39 patients were male, and the median age was 60 years old.
A majority of patients exhibited a good PS (57% with ECOG
PS= 0). The median number of previous chemotherapy line was
two (range from one to seven). The median number of metastatic
sites was three, involving in the majority of cases liver, lung
and lymph nodes. Eighty three percent of patients (n = 63) had
prior resection of the primary tumor. Tumor molecular profiling
was retrieved from clinical documentation when available: 62%
(n= 44/71) wereKRASmutant, 3% (n= 2/58)NRASmutant, 4%
(n= 3/68) BRAF mutant and 20% (n= 6/30) HER2 amplified.
In this cohort no partial response was seen according to
RECIST criteria, and the best response was stable disease (SD) in
32.9% (n = 25/76) of patients. At a median follow-up time of 5.5
months (1.25–56.5 months), median OS was 5.0 months (range
1–52 months) and median PFS was 10 weeks (range 3–52 weeks).
Main toxicities upon treatment were hand-foot syndrome
(46%), hypertension (27%) and skin rash (22%) (summarized
data are reported in Supplementary Table S2). Dose reduction
was required in 41 patients (55%) and 10 patients stopped
treatment due to toxicities (13%).
Sixty five patients (86%) had blood draws available for
subsequent cfDNA analyses. Fifty-seven patients had both
baseline and on-treatment samples, while three cases only had
baseline plasma and five patients only under treatment.
Circulating DNA Markers at Baseline
Quantity of total cfDNA was successfully determined in all
60 patients from whom baseline LB was available. cfDNA
concentration ranged from 4,750 to 4,541,672 genome
equivalents per milliliter (GE/ml). Assessment of cmDNA
was successful in all samples and positivity was observed in
95% (n = 57/60). In the three negative samples (5%), the assay
was unable to detect any methylation signal above the limit of
detection or limit of blank (Figure 2A). This suggests a lack of
sensitivity of the assay, possibly due to very limited DNA release
from these specific tumors or technical issues related to the DNA
extraction process. Another explanation could be the specific site
of metastases in those patients. In two out of the three cmDNA
TABLE 1 | Patient characteristics.
Characteristic (n = 76)
Male gender–no. (%) 39 (51%)
Age–year
Median 60
Range 30–84
WHO performance status–no. (%)
0 43 (57%)
1 33 (43%)
Previous CT line
Median 2
Range 1–7
Primary tumor resected–no. (%) 63 (83%)
Number of metastatic sites
Median 3
Range 1–10
Metastases–no. (%)
Peritoneum 20 (26%)
Liver 50 (66%)
Lung* 49 (65%)
Nodes 35 (46%)
Bone§ 9 (12%)
Other§ 18 (24%)
Molecular profile–no. (%)
KRAS mutation
Available in 71 (93%)
Mutated 44 (62%)
NRAS mutation
Available in 58 (76%)
Mutated 2 (3%)
BRAF mutation
Available in 68 (89%)
Mutated 3 (4%)
Her 2 amplification
Available in 30 (39%)
Mutated 6 (20%)
MSI
Available in 44 (58%)
Mutated 4 (9%)
OS–months
Median 5
Range 1–52
PFS–weeks
Median 10
Range 3–52
Alive–no. (%) 19 (25%)
*75 observations; § 74 observations.
negative cases, metastases were limited to lung and lymph node
or lung only. A correlation was observed between the cmDNA
fraction and the total amount of circulating DNA (expressed
in log(GE/ml) in baseline samples: 0.54 (95%CI: [0.33–0.70];
p= 1.24e-05; Figure 3A).
Forty one patients with baseline LB sample presented archival
tumor tissue mutated for KRAS, NRAS, or BRAF (68.3%), and
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FIGURE 2 | Total amount of cfDNA (expressed as GE/ml), absolute percentage of mutant (genetic) or methylated (cmDNA) alleles, normalized fraction of methylated
cfDNA (cmDNA/ml) in plasma samples drawn at baseline (A) or under regorafenib treatment (B). Patients are stratified according to their PFS. Vertical dotted lines
correspond to median value for cmDNA/ml for each time point.
FIGURE 3 | Correlation among circulating DNA markers measured at baseline (prior to regorafenib treatment). (A) Correlation between total amount of circulating DNA
(measured as GE/ml) and cmDNA. (B) Correlation between cancer specific genetic alteration levels (RAS/BRAF mutant alleles) and cmDNA when both were positive.
38/41 (92.6%) demonstrated concordant status for the expected
patient specific mutations, as supported by more than one
mutational event out of two replicates (Figure 2A). Of note, out
of the 3/41 LB samples found to be negative for mutations, two
were instead positive for cmDNA, while the remaining case was
negative for both genetic and epigenetic alterations. The cmDNA
fraction was informative in all 19 RAS/BRAF wild type patients,
therefore bypassing the need to extensively sequence cancer
tissue and design individualized assays in this subpopulation.
Concordance between positive genetic allelic-ratio and
cmDNA for baseline samples was 0.87 (95%CI: [0.76–0.93]; p=
6.2e-12; Figure 3B), demonstrating the interchangeability of both
marker types when both are informative.
Circulating DNA Markers During Treatment
and Their Dynamics
Sixty two blood samples drawn after regorafenib start were
available (median blood draw time: 14 days (6–75).
Quantity of total cfDNA could be determined in all 62
samples and ranged from 3,764 to 3,810,759 GE/ml. Assessment
of cmDNA was successful in all samples and positivity was
observed in 90% (n = 56/62). Forty patients presented mutated
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tumor (66.7%) and 38/42 (90%) demonstrated positivity in the
on-treatment blood draw (Figure 2B).
We previously observed that changes in circulating DNA
markers during chemotherapy treatment were shown to be
correlated with patient outcome (21). We therefore investigated
the relation between cfDNA markers and outcome upon
regorafenib treatment by comparing cfDNA values at baseline
(before treatment) and at the first blood draw (day 6–75, median:
14) after treatment initiation. Fifty-two patients had blood draw
for both time points.
Contrary to what we previously observed with other drug
regimens, regorafenib induced a significant decrease in cancer
specific markers (genetic or cmDNA; Figures 4A,B) in most
patients regardless of the response status, while total amount of
cfDNA (measured by GE/ml) usually increased upon treatment
(Figure 4C). In order to shed light on this unexpected finding, we
tested whether regorafenib was able to differentially and directly
modulate active release of cfDNA fromnormal ormalignant cells.
However, in-vitro treatment of either non-malignant or cancer
cell lines showed that regorafenib did not significantly affect
cfDNA release (data not shown). One alternative hypothesis is
that the total amount of cfDNA could originate mostly from non-
neoplastic cells due to drug on target and off-target broad effects
on several cell types, tissues, and organs. Partially supporting
this hypothesis, we observed a non-significant increase in total
cfDNA amount (GE/ml) change in patients who required a dose
reduction (due to toxicities) while the cmDNA (expected to
be solely of tumor origin) remained similar between the two
subgroups (Supplementary Figure 1). Therefore, we reasoned
that the cmDNA fraction should be normalized to total amounts
of cfDNA by taking into account the GE/ml, resulting in
cmDNA/ml (calculated by multiplying the cmDNA by GE/ml).
Compared to baseline, we found that this parameter significantly
increases under treatment in patients with fast relapse while it
significantly decrease under treatment in patients achieving ≥16
weeks disease control with regorafenib (Figure 4D).
In a Cox regression model, we confirmed that an increase
in cmDNA/ml from baseline was associated with worst PFS
(Figure 5A) (p= 0.028, HR= 1.78 [95% CI: 1.01–3.13]).
Survival Analysis for Clinico-Pathological
Characteristics and Circulating DNA
Markers
In the univariate analysis, factors significantly associated with
shorter PFS were a high cmDNA/ml fraction at baseline (p =
7.73e-06), baseline LDH (p = 0.0143), and regorafenib dose
reduction (p= 0.036).
There was no statistically significant association between PFS
and either ECOG PS (p = 0.11) or the presence of primary
tumor (p = 0.11) or drug-related toxicity. Age, previous CT line,
baseline CEA and peritoneal metastasis were not significantly
associated with PFS (p = 0.43, p = 0.92, p = 0.42, and p
= 0.85, respectively). In the multivariate analysis, adjusted on
baseline LDH, the amount of cmDNA/ml (as log transformed)
at baseline remained significant (HR: 1.50 [95%CI: 1.23–1.82],
p= 6.03e-05).
By univariate analysis, high cmDNA/ml at baseline
(p= 3.61e-08) and increased bilirubin (p = 0.003) were
associated with worst OS, while presence of hand foot syndrome
associated with better OS (p = 0.019). There was no statistically
significant association between OS and baseline CEA (p =
0.117), baseline LDH (p = 0.079), presence of primary tumor (p
= 0.106), peritoneal metastasis (p= 0.186), and regorafenib dose
reduction (p= 0.083). Age, previous CT line and ECOG PS were
not significantly associated with OS (p= 0.43, p= 0.84, p= 0.96,
respectively). In the multivariate model, the log transformed
cmDNA/ml at baseline remained statistically significant (HR =
1.53 [95%CI: 1.25–1.87], p= 2.72e-05).
We performed in parallel a Cox-regression for OS using
median as a cut-off value for baseline, and we found an
association between high cmDNA/ml at baseline and worst
survival (Figure 5B; HR for death = 3.471, p < 0.0001,
[95% CI: 1.83–6.57]). Since in mCRC PFS is a surrogate
endpoint for OS (24), further analyses were conducted to
explore differences in terms of PFS. Using median as cut-
off on both time points, we found an association between
higher risk of relapse during regorafenib treatment and
high cmDNA/ml at baseline (Figure 5C; HR for progression
= 2.196, p = 0.0015, [95% CI: 1.26–3.84]) and during
treatment (Figure 5D; HR for progression = 2.985, p < 0.0001,
[95% CI: 1.63–5.46]).
DISCUSSION
Due to its stability and cancer specificity, cmDNA could be a
promising source for tumor biomarkers. Recent studies analyzed
the correlation between the methylation status of specific genes
and response to therapy and prognosis in colon and rectal
cancers (25–27).
In the present study, we have shown that by using a
universal five-gene panel, cmDNA was detectable in 57/60
cases, corresponding to 95% of the whole patient population.
In contrast, in the same cohort through the analysis of
candidate hotspot mutations in RAS/BRAF genes by LB, we
were able to detect mutations in plasma cfDNA in only
38/60 patients, corresponding to 95% of cases known to
carry RAS/BRAF mutations in tumor tissue samples, but
only to 63.3% of the entire cohort. This confirmed the
universality of methylation markers for liquid biopsy and their
possible better suitability for large cohort analyses such as
epidemiologic studies.
To overcome the caveats and costs of assessing genetic
alterations in cfDNA by large panels, several studies have
proposed the use of targeting sequencing in archival tissue
to identify cancer patient-specific genetic markers (12, 28–
30). While such approach can certainly improve the specificity
of LB assays, it would undoubtedly increase the costs as
well as the sample processing time (due to optimization of
single variation assay). This is of clinical importance since
absence of candidate mutation would require NGS analysis
of primary tumor and subsequent personal assay design,
impairing the clinical turnaround, and the application of
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FIGURE 4 | Changes in circulating DNA features between baseline plasma samples (abbreviated as BL) and the second plasma time point collected during
regorafenib treatment (labeled as 2nd). For each feature patients were stratified according to their PFS status at 16 weeks. (A) cmDNA, (B) Genetic alterations, (C)
total cfDNA amount in GE/ml, (D) cmDNA/ml. p-values compiled using two-tailed u-test.
cfDNA in prospective analyses. Consequently, methylation
assays might be more prone to be developed into routine
clinically applicable tests for disease monitoring purposes. In
this regard, we note that methylation based assays of cfDNA
have already been proposed for early detection and cancer
classification (31, 32).
We and others demonstrated that cmDNA reflects tumor
burden; since its level correlated with the presence of unresected
primary tumor, of bulky disease or of multiple metastatic lesions,
whereas age and mutational status did not influence the cmDNA
(21, 33, 34). We speculated that longitudinal assessment of
cmDNA during chemotherapy could reflect the dynamics of
tumor burden with a decrease potentially preceding response and
an increase anticipating progression.
In the 52 mCRC patients with both evaluable baseline
and under treatment plasma samples from present study,
we observed a decline in cancer specific cfDNA markers
(genetic or cmDNA) upon treatment with regorafenib that
unexpectedly took place in most cases, while total amount
of cfDNA increased. This behavior of cancer specific markers
was different from what we previously observed using other
anticancer therapies (5FU based chemotherapy, panitumumab
or temozolomide). We therefore speculate that the observed
decrease in cancer specific markers during regorafenib treatment
could be due to a diluting effect by normal DNA shedding
from healthy tissues (possibly due to cytotoxicity) as previously
suggested by a report on a cohort of 20 regorafenib treated
mCRC patients (12). This observation highlights the need
for careful validation of LB assay according to the treatment
used, and warrants fundamental research to improve our
understanding of the factors influencing release of cfDNA by
human cells.
Nevertheless, after normalization, a cmDNA/ml an increase
upon treatment was associated with progressive disease while
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FIGURE 5 | (A) Progression free survival according to cmDNA/ml dynamics (decrease dash line; increase solid line), (B) Overall survival according to baseline
cmDNA/ml, (C) Progression free survival according to baseline cmDNA/ml, (D) Progression free survival according to level of cmDNA/ml under treatment (Low ctDNA
level dash line; High ctDNA solid line).
a decrease was associated with clinical benefit and improved
PFS showing that despite being confounded by normal DNA
release, dynamics of cmDNA was associated with drug activity.
Contrary to conventional chemotherapy or targeted therapy
based regimens which often trigger significant tumor burden
changes, regorafenib seldom induces RECIST responses. The
lack of tumor burden dynamics given by regorafenib is likely to
influence the dynamics of ctDNA levels.
We identified cmDNA/ml at baseline as a prognostic
marker. Through a multivariate cox-regression analysis,
cmDNA/ml maintained a significant impact on both
PFS and OS which was higher than other clinical
variables such as age, previous CT, ECOG PS, presence
of primary tumor, peritoneal metastases, CEA, and
LDH. Consequently, integration of cmDNA/ml as
auxiliary staging parameter might improve patient disease
classification (35).
High values of cmDNA/ml (above median) during treatment
were significantly associated with a higher probability for disease
progression, suggesting that abrogation of ctDNA release needs
to be achieved soon after treatment initiation in order to
observe better PFS. This is in accordance with the literature
demonstrating that early circulating biomarkers change is
associated to clinical benefit (10, 12).
We acknowledge that our study is limited by its retrospective
nature. Recent studies (36, 37) suggested that toxicity might
be related to better prognosis upon regorafenib treatment. In
our dataset, no specific toxicity was associated with improved
PFS, however the need for dose reduction (surrogate for
toxicity related comorbidity) was associated with improved
response duration.
We found a difference in cmDNA/ml levels between
progressing patients and those who achieved clinical benefit.
Nevertheless, the establishment of an optimized threshold to
clearly distinguish between these populations will be needed
to stratify individual patients. Unfortunately, the number of
patients with clinical benefit was relatively small due to the
modest efficacy shown by regorafenib in this setting. Therefore,
modeling an optimal threshold in our cohort was not possible due
to the lack of statistical power. As a consequence, we preferred to
use the median as a natural and unbiased cut-off for this work.
We acknowledge that our study could not provide validation
of such a cut-off in a separate cohort. Future efforts in this
direction will require multicenter enrollment and long term
follow-up to reach a large number of cases with clinical benefit.
This may validate the application of cmDNA/ml for predicting
regorafenib response in individual patients. Nevertheless, this
is the first report investigating the correlation between survival
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and a methylated gene panel in mCRC treated with regorafenib.
Furthermore, data from the present cohort confirmed the general
predictive value of cmDNA in mCRC reported in our previous
work (21). However, the dynamics of the cmDNA may be
affected by different treatments, since we observed a peculiar
decrease in cancer specific markers (genetic or cmDNA) during
regorafenib treatment in most of patients regardless of the
response status warranting its normalization by total amount
of cfDNA.
In conclusion, cmDNA/ml is of prognostic value and is a
dynamic biomarker which longitudinal assessment could be
used relatively early during the treatment of mCRC patients,
before radiological assessment, to identify the patients with a
negative prognosis.
CONCLUSIONS
To conclude, DNA methylation in cfDNA is a cancer
specific biomarker that could be employed to track
response during therapy in mCRC, enabling non-invasive
monitoring of tumor burden. It could be used to select
patients with poor survival who are not likely to benefit from
regorafenib treatment and might allow faster therapeutic
reorientation avoiding overexposure to the drug and possible
side effects.
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